UK markets closed

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
1.6200-0.0330 (-2.00%)
At close: 5:29PM CEST

Allarity Therapeutics A/S

Venlighedsvej 1
Horsholm 2970
Denmark
45 88 74 24 14
http://www.allarity.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees14

Key executives

NameTitlePayExercisedYear born
Mr. Stefano R. CarchediCEO, Pres & Director718.28kN/A1962
Mr. Jens Erik Knudsen CPA, M.B.A.Chief Financial Officer250kN/A1968
Mr. James G. Cullem J.D.Sr. VP of Corp. Devel.235kN/A1969
Dr. Marie Foegh DrSc, M.D.Chief Medical Officer288kN/A1943
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.Co-FounderN/AN/A1955
Dr. Steen Meier KnudsenFounder & Chief Scientific OfficerN/AN/A1961
Ms. Ulla Hald BuhlFounder, COO, Chief IR & CommunicationsN/AN/A1964
Mr. Thomas H. JensenFounder & Sr. VP of Information TechnologiesN/AN/A1978
Mr. Claus Frisenberg PedersenChief Commercial OfficerN/AN/A1972
Ms. Annie RasmussenChief of Clinical OperationsN/AN/A1957
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.

Corporate governance

Allarity Therapeutics A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.